Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation

STOCKHOLM, November 20 - Karolinska Development AB today announced that the European Investment
Fund (EIF) has entered into a co-investment agreement with the company. The
co-investment fund will be managed by Karolinska Development and used to
invest in the company's portfolio of early-stage pharmaceutical and medical
technology companies. EIF has agreed to invest 26.7 M Euros in the
co-investment fund. The agreement represents EIF's largest single investment
in the Nordic region to date.

VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests

SAN DIEGO, November 19 - Accumetrics, Inc., developer of the VerifyNow System, the first
point-of-care method for measuring platelet reactivity, announces that its
market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in
the POPular study, which was presented during a Late Breaking Clinical Trials
session at the American Heart Association's annual Scientific Sessions. The
VerifyNow P2Y12 Test is used to measure the antiplatelet effect of
medications, such as clopidogrel (Plavix(R)), that reduce platelet reactivity
by blocking the platelet P2Y12 receptor.

Medicines Top Counterfeit Concern List in Europe - Consumers Call for Tougher Safety Measures

LONDON, November 19 - Research published today examining consumer opinions on counterfeit drugs
reveals that five per cent of consumers across five European countries
suspect they have received a counterfeit prescription drug and an alarming
one per cent believe they definitely have. This means that as many as 12.8
million consumers could have been exposed to counterfeit drugs in those
markets.

Photos: P&G Voluntarily Recalls Specific Lots of Vicks Sinex Nasal Spray in the United States, Germany and the United Kingdom

CINCINNATI, November 19 - The Procter & Gamble Company (NYSE: PG) announced today it is voluntarily
recalling three lots of its Vicks Sinex nasal spray in three countries: the
United States, Germany and the United Kingdom.

Marketing Authorisation Application for S-1 Validated by European Medicines Agency

TOKYO, November 19 - Taiho Pharmaceutical Company, Ltd. today announced that the Company's
Marketing Authorisation Application (MAA) for S-1, proposed for the treatment
of advanced gastric cancer when combined with cisplatin, was validated by the
European Medicines Agency (EMEA). S-1 was designated as an orphan medicinal
product for the treatment of gastric cancer by the EMEA on 20 December 2007.

International Operation Combats Online Supply of Counterfeit and Illegal Medicines

LYON, France, November 20 - In response to an ever-increasing number of websites supplying dangerous
and illegal medicines, Operation Pangea II, involving 24 countries, was
coordinated by INTERPOL and the World Health Organization's International
Medical Products Anti-Counterfeiting Taskforce (IMPACT) to highlight the
dangers of buying medicines online.

New H1N1 Flu Test Available Now - On Display At MEDICA 2009

2009 H1N1 Flu Test from Quest Diagnostics Now CE Marked For International Distribution under the Simplexa(TM) brand name

AMT Provides Business Update for the Third Quarter 2009

Glybera(R) Clinical Data Presented at Meeting of American Heart Association

AMSTERDAM, November 18 - Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a leader in
the field of human gene therapy, today provides its non-audited business
update in compliance with the EU transparency directive. This report
summarizes material events and AMT's financial position for the third quarter
of 2009.

Mainstay of the Global Workforce - 40-65 Year Olds - Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)

New Report Highlights Global Economic Burden of the Disease

LONDON, November 18 - COPD Uncovered, a new report issued today reveals for the first time that
people between the ages of 40 to 65 are emerging as the new face of this
disease. Authored by Education for Health and other leading experts, the
report uncovers a new, younger majority of COPD patients(1) who are in the
prime of their career, and financially responsible for the care of their
children and aging parents. The authors call for policymakers to read the
report and challenge their thinking on how COPD should be addressed in this
critical age group who are highly depended upon by society as leading wage
earners(2,3).

Teva Launches TevaGrastim(R) (filgrastim)

LEEDS, England, November 18 - Teva UK Limited has signalled its commitment to developing biosimilar
medicines by entering the G-CSF* therapy area. The launch of its proprietary
version of filgrastim, TevaGrastim(R), marks the Company's first biosimilar*,
and represents a major addition to Teva's Hospitals portfolio.

Albireo Announces Positive Clinical Data on A3309 in Patients with Chronic Idiopathic Constipation

GOTHENBURG, Sweden, November 18 - Albireo today announced the completion of a phase 1b study showing a
favourable tolerability and safety profile of A3309 in patients with chronic
idiopathic constipation. In addition, the data revealed appropriate efficacy
signals in this patient population. A3309 is a first in class compound
developed for the treatment of chronic idiopathic constipation and
constipation-predominant Irritable Bowel Syndrome (IBS-C). Based on these
results, Albireo expects to recruit 180 patients with chronic idiopathic
constipation in a US phase 2b study (www.clinicaltrials.gov) under an
IND recently placed into effect by the FDA.

Hard To Treat Diseases (HTDS) Mellow Hope's H1N1 Influenza A Vaccine Successful Registration in Chile

SHENZHEN, China, November 18 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that they have acquired a Registration
Certificate for Mellow Hope's H1N1 Influenza A Vaccine from the government
of Chile and the first vaccines will ship in a matter of weeks.

Apieron Alleges Evidence Shows Aerocrine Inventors Withheld Prior Art Information from Patent Office

Apieron, Inc. Files Motion to Add Additional Invalidity Challenge to Aerocrine Patent

/C O R R E C T I O N — Education for Health/

LONDON, November 18 - In the news release, "Mainstay of the Global Workforce - 40-65 Year Olds
- Hit Hardest by Chronic Obstructive Pulmonary Disease (COPD)" issued on 18
Nov 2009 06:30 GMT, by Education for Health over PR Newswire, we are
advised by a representative of the company that under "References:" the
hyperlink should have read:
"www.educationforhealth.org.uk/_documents/COPD_Pressrelease.pdf"
instead of:
"www.educationforhealth.org.uk/pages/_documents/COPD_Release.pdf"
as originally issued inadvertently.

Health Robotics Announces Worldwide Launch of the "i.v. Room of the Future" Concept at Las Vegas' ASHP

BOZEN, Italy, November 18 - Health Robotics today announced the worldwide presentation and launch of
its revolutionary vision for "The i.v. Room of the Future" at the American
Society of Health-System Pharmacists' Mid-Year Meeting December 6-10 in Las
Vegas, along with an initial consortium of development partners that
currently includes Biomedical Technology Consulting and MEDarchiver.

/C O R R E C T I O N — Teva UK Ltd/

LEEDS, England, November 18 - In the news release, "Teva Launches TevaGrastim(R) (filgrastim)" issued on
18 Nov 2009 07:00 GMT, by Teva UK Ltd over PR Newswire, due to an omission
made by PR Newswire, we did not specify that this is a black triangle drug.
The headline should have read "Teva
Launches TevaGrastim(R) (Black Triangle Drug) (filgrastim)" rather than
"Teva Launches TevaGrastim(R) (filgrastim)" as incorrectly originally
transmitted by PR Newswire. Also, directional details to an accompanying
photo should have been included in the release. Complete, corrected release
follows:

Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products

Network of 53 Hospitals Gain Access to Masimo SET Pulse Oximeters

IRVINE, California, November 18 - Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and
Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that
Lyon, France-based Uni.H.A., one of the largest healthcare Group Purchasing
Organizations (GPO) in France, has signed a multi-year purchasing agreement
for "gold standard" Masimo SET(R) pulse oximeters. The agreement offers
preferred contract pricing to Uni.H.A.'s 53 member hospitals and provides for
more than 1,000 Masimo SET bedside pulse oximeters and 650 handheld pulse
oximeters to be purchased within four-years.

Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'

SHENZHEN, China, November 17 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and
Rubella Combined Vaccine Live) had obtained a "pass" on its First Drug
Evaluation.

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

LEIDEN, The Netherlands, November 17 - Top Institute Pharma (TI Pharma) has formed a
consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and
Maastricht University to define new modalities for the treatment of
hypertension (high blood pressure) and associated vascular complications such
as heart and kidney failure, myocardial infarction and stroke. Based on novel
action mechanisms, new drugs may be discovered with the potential to prevent
vascular complications in patients with hypertension: an opportunity to
improve the quality of life for over a billion people worldwide. This
collaboration, involving 3.4 million euros, 9 new research positions, unique
materials and exchange of know-how, is scheduled to last 3 years.

Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries

Zyomyx's innovative approach enters final phase to become the world's first low-cost, instrument-free test for measuring CD4 T-cell count in HIV/AIDS patients

US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine

KVISTGÅRD, Denmark, November 17 - Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical
Advanced Research and Development Authority) has awarded a new contract to
Bavarian Nordic for the development of a freeze-dried version of its
IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40
million.

Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE

STUDY SHOWS TWO-YEAR SURVIVAL OF 58 PERCENT AND DRAMATIC IMPROVEMENT IN QUALITY OF LIFE FOR HEARTMATE II PATIENTS

FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets

Experts to Re-examine Guidance for Platelet Testing

LAKE ZURICH, Illinois, November 17 - Fenwal, Inc., a global medical technology company focused on improving
blood collection, separation, safety and availability, announced today that
the U.S. Food and Drug Administration has cleared the Verax Platelet PGD(R)
test as a quality control test to detect bacterial contamination in whole
blood-derived, pooled platelets prior to transfusion. Fenwal is the exclusive
global distributor of the test, which was developed by Verax Biomedical of
Worcester, Mass.

Video: Crestor(R) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study

ORLANDO, Florida, November 17 - JUPITER, which used CRESTOR 20 mg, is the first statin study to
demonstrate a reduction in the risk of cardiovascular (CV) events in women
without established cardiovascular disease (CVD). In this new analysis of
6,801 women from the JUPITER study, rosuvastatin 20 mg reduced CV events by
46% in women without CVD but at increased risk of a cardiovascular event, as
identified by age and elevated hsCRP (p=0.002 vs placebo). This analysis also
showed a 42% reduction in CV events for men without established CVD (p<0.001
vs placebo). These data were presented today at the American Heart
Association Annual Scientific Sessions in Orlando, Florida.

ALK Announces Landmark Asthma Prevention Trial

ALK Today Announced the Initiation of its Landmark GRAZAX(R) Asthma Prevention (GAP) Trial.

Frost & Sullivan Reveals Strategies on Turning Challenges into Opportunities in the European Biomarkers Market

LONDON, November 16 - The "omics" revolution of the last decade has ensured that the field of
biomarker research will test the frontiers of biomedical research in the
coming years. New biomarkers are discovered each day and this rapid
development promises excellent growth potential for the biomarker analysis
market. However, due to various challenges faced in biomarker validation and
assay development, there is a huge lag between the time that a biomarker is
discovered in the laboratory and the time it is actually commercialized.

Medical Doctors Confirm "Divine Healing" Cases at the 6th International Christian Medical Conference

KIEV, Ukraine, November 16 - The 6th International Christian Medical Conference was held at the
President Hotel on October 30 and 31, 2009 under the auspices of Ukraine
Organizing Committee of WCDN (World Christian Doctors Network), whose founder
and board chairman is Dr. Jaerock Lee, an evangelical pastor and the author
of many Christian titles.

Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Results Support Flibanserin as a Potential Treatment for HSDD, an Under-Recognised Women's Sexual Health Condition

Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics

Presentation highlights Palomid 529 as a first-in-class dual TORC1/TORC2 inhibitor in Brain Cancer -

ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours

LEUVEN, Belgium and LUND, Sweden, November 16 - ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
trial of their novel anti-cancer monoclonal antibody TB-403 in patients with
advanced solid tumours. The results were presented at the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics in
Boston, U.S. TB-403 was well tolerated with no reported dose limiting
toxicity. These positive data support progression of TB-403 and further
development.

Sanofi-aventis Launches Major New Registry Including Over 10,000 Patients Worldwide With Atrial Fibrillation

The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes

Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial

New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients

Efient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease

ORLANDO, Florida, November 15 - Results from a new study showed patients with type 2 diabetes mellitus
who also had coronary artery disease (CAD) and received a 60 mg loading dose
and 10 mg maintenance dose of Efient(R) (prasugrel) achieved significantly
greater platelet inhibition compared with a 600 mg loading dose and 150 mg
maintenance dose of clopidogrel (Plavix(R)). These data were presented today
at the American Heart Association 2009 Scientific Sessions.

First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes

ORLANDO, Florida, November 15 - Results from the RecordAF registry (REgistry on Cardiac rhythm
disORDers assessing the control of Atrial Fibrillation), presented today at
the Scientific Sessions of the American Heart Association, show that in
recently diagnosed and actively treated patients with atrial fibrillation
(AF), a rhythm-control strategy provides better short term control of the
arrhythmia versus a rate-control strategy but does not translate into a
reduction in the occurrence of clinical events at 1 year. RecordAF also
confirmed that these patients suffer from a high rate of clinical events,
mainly cardiovascular (CV) hospitalisations.

New Intra-Arrest Cooling Method May Save More Brains During Cardiac Arrest

Study Unveiled at AHA Late Breaking 'Best of Best' Presentation Shows Survival Benefit -